BSD Medical Corporation develops, manufactures, markets, and services systems to treat cancer and diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer; internal or interstitial hyperthermia that treats tumors in combination with internal radiation therapy by inserting tiny microwave antennae that deliver hyperthermic microwave energy to tumors through the same catheters used to deliver radioactive materials to tumors for radiation therapy; and deep hyperthermia, which non-invasively treats tumors located deep within the body. It offers MicroThermX-100 and MicroThermX-180 microwave ablation systems for the ablation of soft tissue; BSD-500 systems that deliver superficial or interstitial hyperthermia therapy or both; and BSD-2000 family of products that non-invasively deliver localized therapeutic heating to solid tumors by applying RF energy to certain cancerous tumors, as well as BSD-2000/3D and BSD-2000/3D/MR. The company serves clinics, hospitals, and institutes that treat cancer in the United States, Europe, and Asia. BSD Medical Corporation was founded in 1978 and is based in Salt Lake City, Utah.